An2 Therapeutics, Inc. (ANTX) stock

Add to watchlist

Add holding +

NASDAQ: ANTX Nasdaq Biotechnology Next results ~November 11, 2026

An2 Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Insiders1 buying, 6 selling1 purchase and 22 sales by directors and officers, last 12 monthsInsider trades
Funds43 adding, 28 cuttingOf 16 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 25% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in An2 Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
Share dilution. Diluted shares rose 16.3% in a year.
Volatile shares. Over the past year the shares showed annualised volatility of 134% and a beta of 0.5 against the S&P 500.
Short interest rising. Shares sold short rose 20% in a month to 9.1% of tradable shares.
Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share: -$0.18 against an average estimate of -$0.24: beat by 25.0%
Share reaction: +6.3% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500

An2 Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

1 day-4.0%
1 week+19.8%
1 month-23.8%
This year+281.6%
1 year+253.7%
S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted): $-1.04

Growth

Share count change: +16.3%

Earnings

Last results: August 11, 2026
Next results (est.): November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

August 11, 2026Results

An2 Therapeutics, Inc. reported results

SEC 8-KRead source ↗

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

An2 Therapeutics, Inc. valuation models and calculator

No model value for An2 Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value An2 Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.

Value per share by model
Model	Value per share	In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings.	—	Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years.	—	Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns.	—	Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.	—	Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative.	—	Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out.	—	No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare An2 Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

An2 Therapeutics, Inc.: consensus estimates
Fiscal year	EPS	Growth	Revenue	Growth
Current	−$0.90	+23%	—	0%
Next	−$0.80	+11%	—	0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −6.8% on 90 days ago. In the last 30 days, 1 analyst raised An2 Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast An2 Therapeutics, Inc., last 90 days

Average of analysts' published estimates (third-party data).

View chart data

Period	Current fiscal year	Next fiscal year
90 days ago	−$0.96	−$1.04
60 days ago	−$0.96	−$1.04
30 days ago	−$0.96	−$1.04
7 days ago	−$1.04	−$0.93
Now	−$0.90	−$0.80

Earnings against estimates

An2 Therapeutics, Inc.: reported EPS against the consensus estimate
Quarter to	Estimate	Actual	Surprise
Jun 2026	−$0.24	−$0.18	+25.0%
Mar 2026	−$0.23	−$0.29	−26.1%
Dec 2025	−$0.24	−$0.29	−20.8%
Sept 2025	−$0.22	−$0.31	−40.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026

Buy2100%

Hold00%

Sell00%

Monthly trend

Oct 202622
Sep 202622

Counts of recommendations published by analysts covering An2 Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest: 9.1%
Days to cover: 8.92
Short interest, 1 month: +20%
Held by institutions: 77%
Held by insiders: 16.0%
Employees: 21

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

An2 Therapeutics, Inc.: yearly return, monthly win rate and worst fall against the S&P 500
Calendar year	2023	2024	2025	2026 to date
Return
ANTX	+115%	−93%	−17%	+282%
Industry peers (median)	−18%	−28%	−5%	−27%
S&P 500	+26%	+25%	+18%	+11%
Months that ended higher
ANTX	50%	42%	33%	46%
S&P 500	67%	75%	75%	46%
Largest fall from a high during the year
ANTX	−68%	−95%	−31%	−46%
S&P 500	−10%	−8%	−19%	−9%

Worst fall since March 25, 2022: 96% from August 15, 2022 to August 16, 2024. Getting back needed a 2175% gain, and the shares have not yet recovered.

Price behaviour

52-week range: $1.03 – $6.28
From 52-week high: −30.7%
vs 50-day average: −10.6%
vs 200-day average: +6.5%
Volatility (1 year): 134%
Beta vs S&P 500: 0.52

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day: 6 up, 6 down
After a week: 7 up, 5 down
After a month: 5 up, 7 down

An2 Therapeutics, Inc.: share-price change after each results release
Results released	Next day	S&P 500 next day	5 days	21 days
August 11, 2026	+6.3%	−0.1%	+1.0%	−3.7%
May 11, 2026	−4.3%	+0.1%	+0.4%	−5.8%
March 17, 2026	−1.5%	−1.1%	−19.6%	−33.0%
November 12, 2025	−5.8%	−1.6%	−10.0%	0.0%
March 25, 2025	+0.7%	−1.0%	−8.6%	−14.6%
November 13, 2024	−5.7%	−0.6%	+22.6%	+34.9%
August 13, 2024	+1.9%	+2.0%	+1.9%	+1.0%
May 14, 2024	−3.4%	+1.7%	−7.9%	−15.3%
March 28, 2024	+16.8%	−0.2%	−6.5%	−26.4%
November 9, 2023	−6.2%	+0.8%	+7.7%	+31.4%
August 10, 2023	+2.8%	0.0%	+26.8%	+91.0%
May 11, 2023	+0.4%	−0.3%	+54.4%	+42.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count: +16.3%; year over year

Who owns it

Funds buying and selling

Reported value: $119M
Institutions reporting: 66
Shares held vs prior quarter: ▲ 12.3%
Positions opened / closed: 28 / 14

43 bought 28 sold

Top buyers and sellers, Q2 2026: 43 institutions bought and 28 sold ; the biggest buyer was Blackrock, Inc (+1.3M shares) and the biggest seller Woodline Partners LP (−534K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager	Value	Shares	Share of 13F value	Shares QoQ
Vivo Capital, LLC	$15.3M	3.2M	12.8%	0.0%
Commodore Capital LP	$14.2M	2.9M	11.9%	▲ 25.7%
Millennium Management LLC	$11.2M	2.3M	9.4%	▲ 4.3%
Blackrock, Inc.	$8.1M	1.7M	6.8%	▲ 422.5%
Spruce Street Capital LP	$8M	1.7M	6.8%	0.0%
Almitas Capital LLC	$7.1M	1.5M	6.0%	▼ 0.7%
Vanguard Capital Management LLC	$6M	1.2M	5.0%	▲ 22.5%
Adage Capital Partners Gp, L.L.C.	$4.8M	1.0M	4.1%	0.0%
Citadel Advisors LLC	$4.6M	952K	3.9%	▲ 513.2%
Boxer Capital Management, LLC	$3.6M	749K	3.0%	0.0%
Geode Capital Management, LLC	$3.4M	698K	2.8%	▲ 143.5%
Summittx Capital, L.P.	$2.9M	597K	2.4%	New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not An2 Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart

Insider purchases History → $11,602 1 trade by 1 insider, last 12 months Insider sales History → $398,265 22 trades by 6 insiders · 80% under pre-set plans

Net ▼ $386,663 net selling

Recent insider open-market transactions
Insider	Date	Trade	Shares	Price	Value
Readnour Robin Shane Director	September 9, 2026	Sell pre-set plan	523	$6.02	$3,148
Readnour Robin Shane Director	September 9, 2026	Sell pre-set plan	585	$6.02	$3,522
Readnour Robin Shane Director	September 8, 2026	Sell pre-set plan	5,294	$6.02	$31,870
Readnour Robin Shane Director	September 8, 2026	Sell pre-set plan	4,725	$6.02	$28,444
Readnour Robin Shane Director	September 3, 2026	Sell pre-set plan	3,223	$6.07	$19,564
Readnour Robin Shane Director	September 3, 2026	Sell pre-set plan	2,877	$6.07	$17,463
Fitzpatrick Margaret M Director	September 1, 2026	Buy	2,098	$5.53	$11,602
Williams Sarah Joanne Principal Accounting Officer	September 1, 2026	Sell	272	$5.53	$1,504
Readnour Robin Shane Director	August 17, 2026	Sell pre-set plan	18,706	$6.01	$112,423
Readnour Robin Shane Director	August 17, 2026	Sell pre-set plan	16,696	$6.01	$100,343
Eizen Joshua M See Remarks	July 8, 2026	Sell	5,945	$4.17	$24,791
Williams Sarah Joanne Principal Accounting Officer	May 29, 2026	Sell	265	$4.43	$1,174

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

August 11, 2026
May 11, 2026
March 17, 2026
November 12, 2025
March 25, 2025
November 13, 2024

Recent SEC filings

10-Q Quarterly report August 11, 2026
8-K Current report August 11, 2026
8-K Current report June 9, 2026
8-K Current report June 4, 2026
10-Q Quarterly report May 11, 2026
8-K Current report May 11, 2026
DEF 14A Proxy statement April 22, 2026
S-3 S-3 April 9, 2026

Data status

When each part of this page on An2 Therapeutics, Inc. was last updated.

Data	Last updated	Source
Share price	November 2, 2026	Exchange closing prices
News and updates	October 31, 2026, 7:55pm ET	Company releases and SEC 8-K filings
Analyst estimates	October 31, 2026, 9:12am ET	Aggregated analyst estimates
Valuation and scores	November 3, 2026, 9:09am ET	Our models, from the filed figures

How we build and check these figures: methodology and data sources.

An2 Therapeutics, Inc. in brief

What does An2 Therapeutics, Inc. do?: An2 Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is An2 Therapeutics, Inc.'s stock ticker?: An2 Therapeutics, Inc. trades under the ticker ANTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are An2 Therapeutics, Inc.'s largest institutional shareholders?: By value reported in 13F filings for June 30, 2026, the largest reported holders are Vivo Capital, LLC, Commodore Capital LP and Millennium Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling An2 Therapeutics, Inc. stock?: Over the last 12 months, An2 Therapeutics, Inc.'s directors and officers reported 1 open-market purchases and 22 sales on Form 4. The insider trading page charts every trade.
When is An2 Therapeutics, Inc.'s next earnings date?: Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — An2 Therapeutics, Inc. announces its own schedule.